Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Post Marketing New Adverse Effects of Oral Therapies in Multiple Sclerosis: A Systematic Review Publisher Pubmed



Sahraian MA1 ; Salehi AM2 ; Jenabi E3 ; Esfahani ME4 ; Ataei S4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Student of medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
  3. 3. Autism Spectrum Disorders Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
  4. 4. Department of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran

Source: Multiple Sclerosis and Related Disorders Published:2022


Abstract

Background: There is a lack of safety information about the post-marketing adverse effects of several disease-modifying drugs (DMDs) used to control multiple sclerosis (MS). Investigating the post-marketing side effects is required to manifest the safety of the appropriate therapy. Therefore, the present systematic review aimed to identify disease-modifying drugs used to control multiple sclerosis attacks and progress. Methods: The Web of Science, PubMed, and Scopus databases were searched for studies published until November 2020 based on the research strategy terms. Inclusion criteria involved all full texts exploring disease-modifying drugs used to control multiple sclerosis based on case reports and case series studies. The Joanna Briggs Institute (JBI) critical appraisal checklist was used to assess the quality of case report studies. Results: In total, 25 articles that met the criteria for inclusion were retrieved in the present systematic review. The most side effects were observed with fingolimod and teriflunomide, respectively, while dimethyl fumarate had minor side effects. Conclusion: The oral therapies have some significant post-marketing adverse effects that have been diagnosed in numerous case reports. Some of them are serious and must be noticed by neurologists. Accordingly, in this review, we assessed the post-marketing adverse effects of oral therapies for multiple sclerosis. © 2022
Related Docs
View other Related Docs
1. Consensus Recommendations for Diagnosis and Treatment of Multiple Sclerosis: 2023 Revision of the Menactrims Guidelines, Multiple Sclerosis and Related Disorders (2024)
2. Consensus Recommendations for the Diagnosis and Treatment of Multiple Sclerosis: 2019 Revisions to the Menactrims Guidelines, Multiple Sclerosis and Related Disorders (2020)
3. The Efficacy and Safety of Oral Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Current Journal of Neurology (2020)
4. A Comprehensive Review on the Treatment Approaches of Multiple Sclerosis: Currently and in the Future, Inflammation Research (2019)
5. Comparable Efficacy and Safety of Teriflunomide Versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis, Neurology Research International (2021)
6. Consensus Recommendations for the Diagnosis and Treatment of Multiple Sclerosis: The Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis (Menactrims), Current Medical Research and Opinion (2015)
7. Multiple Sclerosis: Clinical Features, Pathophysiology, Diagnosis, and Management, Neuroinflammation (2018)
8. Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing–Remitting Multiple Sclerosis Patients? a Narrative Review, Neurology and Therapy (2020)
Experts (# of related papers)
View all Related Experts
Mohammad Ali Sahraian (7)
Shahrokh Karbalahi Saleh (1)
Other Related Docs
9. Characterization of Cd4+ and Cd8+ T Cell Subsets and Interferon Regulatory Factor 4 (Irf4) in Ms Patients Treated With Fingolimod (Fty-720); a Follow-Up Study, Iranian Journal of Allergy# Asthma and Immunology (2018)
10. Safety and Efficacy of Fingolimod in Iranian Patients With Relapsing-Remitting Multiple Sclerosis: An Open-Label Study, Caspian Journal of Internal Medicine (2021)